Question 5924 — diseases

Summary

The specialty to which reference is made: xofigo® (radium dichloride) has been covered by health insurance since 2014. Health establishments can therefore obtain and use this product which is financed from the rates for hospitalization services. However, this product is not reimbursed like the products listed on the list of specialties billable in addition to hospitalization services (“list in addition ") reserved for innovative and expensive medicines. Indeed, the High Authority for Health, responsible for the evaluation of medicines, considered in its opinions of April 2, 2014 and June 22, 2016, that this product only provides a minor improvement in actual benefit and that the medicines with which this product can be compared are not included on the list in addition. Since that date, there has been no new element that could justify a modification of the decision not to register on the list in addition. There are nevertheless therapeutic alternatives to the specialty xofigo® such as the specialty xtandi®.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.